Compare Crown Castle International Corp (CCI) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crown Castle International Corp vs Crispr Therapeutics AG — how do they compare? Crown Castle International Corp trades at $73.8 (market cap $31.33B), while Crispr Therapeutics AG trades at $53.9 (market cap $5.23B). The key difference: Crown Castle International Corp is far larger — about 6× Crispr Therapeutics AG's market cap, and Crown Castle International Corp pays a 5.77% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CCI | CRSP | |
|---|---|---|
Market Cap | $31.33B | $5.23B |
Sector | Real Estate | Health |
52-Week High | $103.79 | $76.78 |
52-Week Low | $73.61 | $44.34 |
Enterprise Value | $53.69B | $3.65B |
Dividend Yield | 5.77% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
